RESUMO
The p53 tumor suppressor protein has been implicated as a mediator of programmed cell death (PCD). A series of nontransformed mammary epithelial cell (MEC) lines were used to correlate p53 function with activation of PCD. Treatment of MECs expressing mutant, inactive, or no p53 with DNA-damaging agents did not induce apoptosis. Upon introduction of temperature-sensitive p53 into HC11 cells, which lack wild-type (wt) p53, PCD was observed after mitomycin treatment at 32 degrees, when the ts p53 protein is in wt conformation. Thus, wt p53 mediates activation of PCD in response to mitomycin in HC11 cells. Treatment of the MCF10-A cells, which express wt p53, with various DNA-damaging agents led to nuclear accumulation of p53. Only mitomycin treatment led to an increase in the number of apoptotic nuclei. ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. A combination of high cell density and serum-free medium induces apoptosis in all MECs tested, irrespective of their p53 status. Under these conditions, EGF or insulin act as survival factors in preventing PCD. These data might elucidate some aspects of breast involution and tumorigenesis.
Assuntos
Apoptose/efeitos dos fármacos , Proteína Supressora de Tumor p53/farmacologia , Animais , Mama/metabolismo , Contagem de Células , Células Cultivadas , Meios de Cultura Livres de Soro , Fator de Crescimento Epidérmico/farmacologia , Humanos , Insulina/farmacologia , Glândulas Mamárias Animais/metabolismo , Mitomicinas/farmacologia , Proteína Supressora de Tumor p53/antagonistas & inibidores , Vincristina/farmacologiaRESUMO
Twenty-six primary breast tumors were examined for mutations in the p53 tumor suppressor gene by an RNase protection assay and nucleotide sequence analysis of PCR-amplified p53 complementary DNAs. Each method detected p53 mutations in the same three tumors (12%). One tumor contained two mutations in the same allele. Single strand conformation polymorphism analysis of genomic DNA and complementary DNA proved more sensitive in the detection of mutations. Combining this technique with the other two a total of 12 mutations in the p53 gene were demonstrated in 11 tumors (46%), and a polymorphism at codon 213 was detected in another tumor. Loss of heterozygosity on chromosome 17p was detected by Southern blot analysis in 30% of the tumor DNAs. Not all of the tumors containing a point mutation in p53 also had loss of heterozygosity of the remaining allele, suggesting that loss of heterozygosity may represent a later event.
Assuntos
Neoplasias da Mama/genética , Genes p53 , Mutação , Sequência de Bases , Mapeamento Cromossômico , DNA de Neoplasias/análise , Feminino , Heterozigoto , Humanos , Dados de Sequência Molecular , Polimorfismo de Fragmento de Restrição , RNA Neoplásico/análiseRESUMO
The gene for the human DF3 breast carcinoma-associated antigen contains a conserved (G + C)-rich 60-base pair tandem repeat and maps to chromosome 1q21-24. In the present study we isolated and characterized 1220 base pairs of nonrepetitive adjacent sequences. Multiple alleles were identified by fragment size. Signal intensity of hybrids with the tandem and unique sequence probes indicated that allelic variation is due to different numbers of repeats. Probes for both the tandem and the unique sequences were used to study the DF3 locus in human breast tumor DNAs. Seventy of 110 breast tumor DNAs were informative at the DF3 locus. Of these, 20 (29%) showed a loss of heterozygosity, while eight (11%) had an increased copy number of one allele. In some cases, the loss of heterozygosity or increased copy number did not extend to other markers on chromosome 1q or 1p. These data indicate that the chromosomal region around the DF3 locus is affected by mutations at high frequency.
Assuntos
Antígenos de Neoplasias/genética , Biomarcadores Tumorais , Neoplasias da Mama/genética , Carcinoma/genética , Sequência de Aminoácidos , Sequência de Bases , Mapeamento Cromossômico , Cromossomos Humanos Par 1 , Células Clonais , DNA/genética , DNA de Neoplasias/genética , Humanos , Dados de Sequência Molecular , Hibridização de Ácido NucleicoRESUMO
Gene amplification is a relatively frequent event in human malignant tumors and is believed to have an important function in neoplastic transformation and tumor progression. Our attention has been focused on the amplification and the expression of the int-2 gene for several reasons: (1) In the mouse mammary tumorigenesis int-2 is frequently activated by MMTV proviral integration. (2) The human homolog of int-2, located on chromosome 11q13, is frequently amplified in human primary tumors and is comprised in an amplification unit encompassing the hst gene, which is often coamplified; the amplification at the 11q13 locus in breast carcinomas correlates with a poor outcome of the disease. (3) int-2 and hst belong to the basic FGF gene family. All these observations raise the possibility that the human int-2 gene plays an active role in the neoplastic process, but this will prove to be true only if int-2 is expressed in human tumors. In the present study we used RNA:RNA in situ hybridization and Northern blot analysis to show that int-2 gene is expressed in a number of human carcinomas amplified at the same locus.
Assuntos
Amplificação de Genes , Neoplasias/genética , Proteínas Proto-Oncogênicas/genética , RNA Mensageiro/análise , Proteínas de Peixe-Zebra , Northern Blotting , Southern Blotting , Mapeamento Cromossômico , Humanos , Hibridização de Ácido Nucleico , Proteínas WntRESUMO
p53 mutations are frequent in human breast cancer. In order to understand the role of p53 in the context of the accumulation of mutations in breast cancer, a model of non transformed mammary cells was sought. The HC11 cells are immortalized, non transformed rodent mammary epithelial cells which synthesize milk proteins following stimulation with lactogenic hormones. p53 protein was readily detected in HC11 protein extracts with the PAb421 antibody. Two mutations were identified in the p53 cDNA from HC11 cells: a missense mutation at codon 138, substituting Trp for Cys, and a microdeletion, codon 123 to 130, of exon 5. The latter results from an intronic mutation of the splice acceptor site at the intron 4/exon 5 junction. The mutations affect separate p53 alleles, and no wt allele was found. Wt p53 was introduced into HC11 cells by means of a retroviral vector, under the control of a Cd(++)-inducible promoter. In the presence of CdSO4 a dramatic growth inhibition was observed. A temperature-sensitive mutant p53 gene was also transfected into HC11 cells. This resulted in a marked inhibition of cells growth at 32 degrees C, when the p53 is in the wt conformation, while no effect was observed at 37 degrees C, when the mutant conformation is predominant. wt p53-mediated inhibition of monolayer growth does not involve induction of programmed cell death and does not activate de novo synthesis of differentiation-specific milk proteins. We conclude that mutations in the p53 gene likely played a role in their immortalization. The HC11 cells provide a model for assessing the cooperative action of other mutations in mammary tumorigenesis.
Assuntos
Genes p53/fisiologia , Glândulas Mamárias Animais/citologia , Mutação/genética , Alelos , Animais , Sequência de Bases , Southern Blotting , Divisão Celular/genética , Linhagem Celular , DNA/genética , Células Epiteliais , Epitélio/química , Éxons , Feminino , Deleção de Genes , Glândulas Mamárias Animais/química , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Testes de Precipitina , RNA Mensageiro/análise , RNA Mensageiro/genética , Ratos , TransfecçãoRESUMO
In both experimental and spontaneous tumors, c-myc expression is often enhanced following its amplification or its rearrangement adjacent to a strong promotor/enhancer. However, c-myc by itself does not induce foci efficiently in fibroblast cultures. The effect of high levels of c-myc expression from a retroviral construct was investigated in several rodent fibroblast cell lines grown in medium containing 10% fetal calf serum or in serum-free PC-1 medium. c-myc-infected NIH3T3 clone 7 cells exhibited efficient quantitative focus formation when grown in PC-1 medium, whereas foci were not detected when grown in serum-supplemented medium. NIH3T3 clone 7 was the only cell line found to be sensitive to c-myc; other clones of NIH3T3 or other rodent fibroblast cell lines proved to be resistant to c-myc focus formation. At least two major types of morphologically distinct c-myc-induced foci were observed; the first was similar to ras-transformed foci induced in NIH3T3 and other fibroblast cell lines, and the second type was composed of adipocyte-like cells similar to NIH3T3 L1 cells. The c-myc infected cells cloned from these two types of foci expressed high levels of retrovirus-derived c-myc RNA and exhibited elevated levels of immunoreactive myc protein, as detected by immunofluorescent staining with an anti-myc polyclonal antibody. c-myc-transformed clones displayed only a limited ability to grow in soft-agar in the presence of serum and were not tumorigenic in nude mice. Focus formation by c-myc was quantitatively inhibited by the addition of interferon alpha + beta (INF alpha, beta), tumor necrosis factor alpha (TNF alpha) or transforming growth factor beta 1 (TGF beta 1) to the serum-free PC-1 medium, and, in correlation, NIH3T3 clone 7 cells produced the lowest level of endogenous TGF beta of the various cell lines tested.
Assuntos
Proteínas Sanguíneas/farmacologia , Fibroblastos/efeitos dos fármacos , Substâncias de Crescimento/farmacologia , Proteínas Proto-Oncogênicas/fisiologia , Animais , Linhagem Celular , Fibroblastos/metabolismo , Expressão Gênica/efeitos dos fármacos , Interferon Tipo I/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-myc , Proto-Oncogenes , Ratos , Fatores de Crescimento Transformadores/metabolismo , Fatores de Crescimento Transformadores/farmacologia , Fator de Necrose Tumoral alfa/farmacologiaRESUMO
Dlx genes comprise a highly conserved family of homeobox genes homologous to the distal-less (Dll) gene of Drosophila. They are thought to act as transcription factors. All Dlx genes are expressed in spatially and temporally restricted patterns in craniofacial primordia, basal telencephalon and diencephalon, and in distal regions of extending appendages, including the limb and the genital bud. Most of them are expressed during morphogenesis of sensory organs and during migration of neural crest cells and interneurons. In addition, Dlx5 and Dlx6 are expressed in differentiating osteoblasts. Gene targeting of Dlx1, Dlx2, Dlx3 and Dlx5 in the mouse germ-line has revealed functions in craniofacial patterning, sensory organ morphogenesis, osteogenesis and placental formation. However, no effect on limb development has yet been revealed from gene inactivation studies. A role for these genes in limb development is however suggested by the linkage of the Split Foot/Hand Malformation human syndrome to a region containing DLX5 and DLX6. As for most transcription factors, these genes seem to have multiple functions at different stages of development or in different tissues and cell types.
Assuntos
Drosophila/genética , Proteínas de Homeodomínio/fisiologia , Fatores de Transcrição , Sequência de Aminoácidos , Animais , Encéfalo/embriologia , Proteínas do Citoesqueleto , Proteínas de Ligação a DNA/metabolismo , Embrião de Mamíferos/metabolismo , Embrião não Mamífero , Regulação da Expressão Gênica no Desenvolvimento , Hematopoese , Proteínas de Homeodomínio/metabolismo , Humanos , Camundongos , Dados de Sequência Molecular , Osteogênese , Proteínas de Ligação a RNA , Órgãos dos Sentidos/embriologia , Homologia de Sequência de Aminoácidos , Fatores de TempoRESUMO
The HC11 mouse mammary epithelial cells are a useful in vitro model of mammary cell differentiation. When treated with the lactogenic hormones mix dexamethasone, insulin and prolactin (DIP) these cells synthesize the milk protein beta-casein. HC11 cells express receptor tyrosine kinases (RTK) of various subclasses. Here we present an analysis of the effect of their stimulation on growth, differentiation and survival. Growth conditions are an important part in the HC11 cell differentiation program. In order to respond optimally to DIP, cells must be grown to confluency in medium containing epidermal growth factor (EGF) plus insulin, at which stage the cells are defined as competent. During the growth phase all the peptide factors rested in this study: EGF, fibroblast growth factor (FGF)-2, insulin, IGF-I, platelet-derived growth factor (PDGF) and stem cell factor (SCF), stimulated MAP kinase (ERK2) activity and-DNA synthesis. However, not all factors were equivalent in promoting competency. Only FGF-2 replaced EGF during growth, while IGF-1 or SCF were able to substitute for insulin. PDGF replaced neither EGF nor insulin and was ineffective as a competence factor. The only peptide which could substitute for insulin in the lactogenic DIP mix and induce beta-casein synthesis was IGF-1, albeit at a high concentration. Competent cultures of HC11 cells maintained in serum-free medium in the presence of only dexamethasone and prolactin undergo apoptosis, which is prevented by the addition of either insulin, IGF-1, FGF-2, or EGF, but not PDGF or SCF. We conclude that in HC11 cells all peptide factors induce DNA synthesis but have distinct effects on differentiation and survival in HC11 cells.
Assuntos
Substâncias de Crescimento/farmacologia , Glândulas Mamárias Animais/efeitos dos fármacos , Mitógenos/farmacologia , Receptores Proteína Tirosina Quinases/agonistas , Sequência de Aminoácidos , Animais , Proteínas Quinases Dependentes de Cálcio-Calmodulina/metabolismo , Caseínas/biossíntese , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , DNA/biossíntese , Ativação Enzimática , Células Epiteliais , Epitélio/efeitos dos fármacos , Feminino , Glândulas Mamárias Animais/citologia , Camundongos , Proteína Quinase 1 Ativada por Mitógeno , Dados de Sequência Molecular , Proteínas Tirosina Quinases/metabolismo , Receptores Proteína Tirosina Quinases/fisiologiaRESUMO
Control mechanisms of normal differentiation are disrupted in cancer cells but can be restored by treatment with site-selective cAMP analogs. The cellular events associated with such changes entail compartmental redistribution of the cAMP-dependent protein kinase type II regulatory subunit, RII beta. The results of this study indicate that the molecular mechanisms of action involve changes in specific DNA-binding activity of putative transcription factors. Gel retardation analyses revealed that nuclear extracts from cells of various human cancer cell lines [colon cancer (LS-174T), gastric cancer (TMK-1), and leukemia (K-562)] and rodent pheochromocytoma (PC12) show a concentration-dependent increase in binding activity to a synthetic DNA that contained the cAMP-responsive element 5'-TGACGTCA-3' after treatment with 8-Cl-cAMP. Such an increase in cAMP-responsive element binding activity was not observed in the 8-C1-cAMP-unresponsive MKN-1 gastric cancer cells. These findings indicate that the antitumor activity of site-selective cAMP analogs may reside in the induction of transcription factors that restore normal gene regulation in cancer cells.
Assuntos
8-Bromo Monofosfato de Adenosina Cíclica/análogos & derivados , Antineoplásicos , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , DNA de Neoplasias/metabolismo , Proteínas de Ligação a DNA/metabolismo , Transcrição Gênica/efeitos dos fármacos , Células Tumorais Cultivadas/efeitos dos fármacos , 8-Bromo Monofosfato de Adenosina Cíclica/farmacologia , Animais , Sítios de Ligação , Linhagem Celular , Núcleo Celular/metabolismo , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico , Humanos , Células Tumorais Cultivadas/metabolismoRESUMO
We demonstrate that PCR amplification of human genomic DNA can be used for the detection of loss of heterozygosity (LOH) in tumor samples. A 250-bp fragment containing codon 72 of the human p53 gene was amplified, ThaI digested and electrophoresed. Tumor LOH is detectable both by ethidium bromide staining and autoradiography, despite 25% contamination with normal DNA. This technique provides a fast and reproducible alternative to conventional Southern blotting and has minimal sample requirements.
Assuntos
DNA de Neoplasias/genética , Triagem de Portadores Genéticos , Reação em Cadeia da Polimerase/métodos , Sequência de Bases , Southern Blotting , Neoplasias da Mama/genética , DNA de Neoplasias/isolamento & purificação , Humanos , Dados de Sequência MolecularRESUMO
We examined the status of the p53 gene in the HC11 normal mammary epithelial cells. Two mutations were identified: a Cys to Trp change at codon 138 and a microdeletion of codon 123 to 130 resulting from mutation of the splice acceptor site. These two mutations were independent, and no wild-type p53 allele was found. Introduction of wt-p53 strongly inhibited growth in monolayer. Thus, the absence of wt-p53 can be sufficient for the immortalization of mammary cells.
Assuntos
Compostos de Cádmio , Divisão Celular/fisiologia , Genes p53 , Glândulas Mamárias Animais/citologia , Sulfatos , Transfecção , Sequência de Aminoácidos , Animais , Cádmio/farmacologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Códon , Células Epiteliais , Éxons , Cinética , Mutação Puntual , Reação em Cadeia da Polimerase , Roedores , Deleção de SequênciaRESUMO
The short area of chromosome 17 is a frequent target for deletions in human tumors, including breast cancer. We have investigated by restriction fragment polymorphism analysis the pattern of loss of heterozygosity (LOH) at four loci on 17p13.1-17pter in a panel of 110 primary human breast carcinomas. A copy of the p53 gene was lost in 23% of the informative cases. Point mutations in the p53 gene were statistically associated with LOH at the same locus (p = 0.003) but not at other loci on 17p13.3-17pter. A second region bordered by the loci D17S5/D17S28 (17p13.3) and D17S34 (17pter) is also affected by LOH, independent of point mutations in the p53 gene. We propose the presence of a second tumor suppressor gene within this region. In support of this hypothesis is the significant association (p = 0.005) between LOH at the D17S5/D17S28, but not at the TP53 or D17S34 loci, and tumors having a high S-phase index.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Genes Supressores de Tumor/genética , Fase S/genética , Alelos , Deleção Cromossômica , Genes p53 , Heterozigoto , Humanos , Mutação Puntual/genética , Reação em Cadeia da PolimeraseRESUMO
We have undertaken a systematic study of primary human breast tumor DNAs to identify and characterize frequently occurring somatic mutations. Loss of heterozygosity (LOH) was found on chromosomes 1p (37%), 1q (20%), 3p (30%), 7 (41%), 13q (30%), 17p (49%), 17q (29%) and 18q (34%) in our tumor DNA panel. Specific subsets of tumors could be defined based on the particular collection of mutations they contained. One goal of these studies has been to determine whether there is a significant association between specific mutations and clinical parameters of the disease. We have found that LOH on chromosome 17p in tumor DNAs is associated with breast tumors having a high proliferative index and that LOH on chromosome 7 is associated with patients having a poor prognosis. Our analysis of chromosome 17 suggests that there may be as many as four tumor suppressor genes affected in primary human breast tumors.
Assuntos
Neoplasias da Mama/genética , Animais , Neoplasias da Mama/patologia , DNA de Neoplasias/genética , Variação Genética , Humanos , Camundongos , Camundongos Transgênicos , MutaçãoAssuntos
Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Cromossomos Humanos Par 17 , Genes p53 , Mutação Puntual , Southern Blotting , Mapeamento Cromossômico , Cromossomos Humanos Par 1 , Cromossomos Humanos Par 13 , Cromossomos Humanos Par 3 , Éxons , Feminino , Humanos , Reação em Cadeia da Polimerase , Fase SRESUMO
A systematic study of primary human breast tumor DNA demonstrated that three proto-oncogenes or regions of the genome (c-myc, int-2, and c-erbB2) are frequently amplified and that there is loss of heterozygosity (LOH) on chromosomes 1p(37%), 1q(20%), 3p(30%), 7(41%), 11p(20%), 13q(30%), 17p(49%), 17q(29%), and 18q(34%). Specific subsets of tumors can be defined based on the particular collection of mutations they contain. For instance, LOH on chromosomes 11p, 17p, and 18q frequently occurs in the same tumor. A search for putative tumor suppressor genes within the regions of the genome affected by LOH has been started. In a comprehensive molecular analysis of the p53 gene on chromosome 17p, 46% of the tumors contained a point mutation in the p53 gene.
Assuntos
Neoplasias da Mama/genética , DNA de Neoplasias/análise , Mutação , Humanos , Mutação/genética , Proto-Oncogenes/genéticaRESUMO
A series of 121 human breast tumors was screened for point mutations in exons 5 through 8 of the p53 gene, by SSCP analysis. On the same tumor samples, the S-phase index (SPI) was determined by the incorporation of BUdR in fresh tissue. p53 mutations were observed in 29% of the cases. The frequency of point mutations for the individual exons was: exon 5, 10.0%; exon 6, 9.9%; exon 7, 7.1% and exon 8, 5.5%. Two mutations detected by SSCP were confirmed by sequencing the p53 cDNA. The presence of a p53 mutation, irrespective of its location, correlates (p = 0.003) with a high SPI. This association appears to primarily reflect mutations in exon 5 (p = 0.0002) and exon 6 (p = 0.05), since mutations in exons 7 and 8 failed to show any association. These results indicate that mutations in the p53 gene identify highly proliferating tumors, and that the position of the p53 mutation may have different effects upon the proliferative activity of tumor cells in vivo.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Éxons/genética , Genes p53/genética , Mutação/genética , Fase S/genética , Sequência de Bases , Neoplasias da Mama/patologia , Divisão Celular/genética , Análise Mutacional de DNA , Feminino , Humanos , Dados de Sequência Molecular , Reação em Cadeia da Polimerase/métodosRESUMO
The int-2 protein is related to basic fibroblast growth factor (bFGF) by amino acid sequence homology. To assess its biological activity, we constructed retroviral vectors containing four variants of mouse int-2 complementary DNA under the transcriptional control of the beta-actin promoter and tested their effects on human SW13 adrenal cortical tumor cells. This cell line specifically requires bFGF, interleukin 1, or transforming growth factor e for anchorage-independent growth in soft agar. Despite encoding a signal sequence that should direct the protein to the secretory pathway, vectors containing unmodified int-2 complementary DNA, or a form optimized for translation initiation at the AUG codon, were incapable of inducing SW13 growth in soft agar. However, SW13 transfectants expressing a construct (pSP1), in which a mouse immunoglobulin signal peptide sequence is linked to the int-2 coding sequences, grew well in soft agar. The concentrated conditioned medium from these pSP1-transfected cells supported anchorage-independent growth of SW13 indicator cells and competed with bFGF for binding to receptors. Western blot analysis with an int-2-specific antiserum detected Mr 30,000-32,000 int-2 products in cell extracts and conditioned medium from pSP1-transfected clones, whereas the conditioned medium from these and other SW13 clones contained only low levels of bFGF as measured in a specific radioimmunoassay. These data suggest that the product of the int-2 gene can functionally replace bFGF in modulating the anchorage-independent growth of SW13 cells.
Assuntos
Fator 2 de Crescimento de Fibroblastos/genética , Fatores de Crescimento de Fibroblastos , Expressão Gênica/fisiologia , Proteínas Proto-Oncogênicas/fisiologia , Sequência de Aminoácidos , Animais , Sequência de Bases , Linhagem Celular , Meios de Cultura , Fator 3 de Crescimento de Fibroblastos , Vetores Genéticos , Camundongos , Dados de Sequência Molecular , Proteínas Proto-Oncogênicas/genética , Radioimunoensaio , Ensaio Radioligante , Proteínas Recombinantes/genética , Retroviridae/genética , Transfecção/genéticaRESUMO
Mutations in the p53 tumour suppressor gene, with consequent accumulation of the p53 protein, are frequently observed in non-small cell lung cancer (NSCLC). Little is known, however, about the timing of their appearance or their maintenance through cancer progression and metastatic spread. We have examined the normal epithelium and a panel of bronchial lesions, including dysplastic, neoplastic, and metastatic lesions, for p53 immunoreactivity and for expression of proliferating cell nuclear antigen (PCNA). No p53 immunoreactivity was found in normal and hyperplastic epithelium, nor in squamous metaplastic lesions. Twenty out of 30 invasive tumours and 13 out of 17 in situ carcinomas adjacent to an invasive tumour showed p53 immunoreactivity. There was a strict correlation between the level of p53 expression in the non-invasive and the invasive components of the tumours. Five out of eight pairs of primary tumours and matching metastases expressed p53, at identical levels in both compartments. These data indicate that p53 overexpression can occur in the earliest recognized phase of NSCLC and that the alteration is maintained during progression from in situ to invasive carcinoma and metastatic spread. PCNA expression increased from early to advanced phases of NSCLC. High PCNA immunoreactivity was observed in tumours expressing high p53 levels. A significant association was observed for PCNA expression between preinvasive and invasive lesions.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/química , Neoplasias Pulmonares/química , Proteínas de Neoplasias/análise , Lesões Pré-Cancerosas/química , Proteína Supressora de Tumor p53/análise , Antígenos de Neoplasias/análise , Brônquios/patologia , Carcinoma in Situ/química , Carcinoma Pulmonar de Células não Pequenas/secundário , Progressão da Doença , Humanos , Hiperplasia/metabolismo , Técnicas Imunoenzimáticas , Metaplasia/metabolismo , Invasividade Neoplásica , Antígeno Nuclear de Célula em Proliferação/análiseRESUMO
The capacity of breast tumor cells to proliferate is considered a potential prognostic factor together with other histopathologic parameters. The authors determined the proliferation index on a large panel of human primary breast tumors by measuring the levels of incorporation of bromodeoxyuridine (BrdU) by fresh tumor specimens in culture. Previous analysis showed that the percentage of cells entering the S-phase of the cell cycle strongly correlates with tumor grade, tumor size, and estrogen and progesterone receptor status. The capacity of tumor cells to proliferate might be associated with specific genetic mutations in primary tumors. To test this hypothesis, a panel of 96 human breast carcinomas, for which the BrdU labeling index (LI) was known, were tested for loss of heterozygosity (LOH) or increased copy number (ICN) at chromosomes 1q, 3p, 13q, 17p, and 18q. On chromosome 17p, LOH and ICN were observed in 27% and 12%, respectively, of the informative breast tumors. The LOH on chromosome 17p was significantly associated with tumors having an elevated BrdU proliferation index (P = 0.022). No association (P = 0.45) was observed between BrdU LI and tumor size (T2 + T3 compared with T1), tumor grade, and lymph node status. Increased copy number on chromosome 17p, LOH or ICN on 1q, and LOH on 13q14, 18q, and 3p also showed no significant correlation with cell kinetic parameters. These data are consistent with the presence of a gene or genes on chromosome 17p13 near the YNZ22.1 locus whose normal functioning is necessary for controlling breast tumor cells proliferation in vivo.
Assuntos
Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/patologia , Cromossomos Humanos Par 17 , Heterozigoto , Southern Blotting , Bromodesoxiuridina/metabolismo , Divisão Celular , DNA de Neoplasias/genética , DNA de Neoplasias/metabolismo , Humanos , Índice Mitótico , Timidina/metabolismoRESUMO
We have reported that bcl-2 is expressed in normal human thyroid epithelium and that its expression is down-regulated in undifferentiated thyroid tumors. Production of IL-6 was concomitantly down-regulated in these forms. Based on these observations, we analyzed whether insertion of bcl-2 would reverse the highly malignant phenotype of a thyroid cell line (ARO) derived from an undifferentiated carcinoma. This cell line fails to produce Bcl-2 and IL-6. By infection with a bcl-2 retroviral vector, ARO cells expressing bcl-2 (ARObcl-2) were obtained. Compared with parental cells, expression of bcl-2 was associated with enhancement of growth potential (DNA synthesis, in vitro proliferation rate, anchorage-independent growth in semi-solid media). Chemotaxis and invasive potential in Boyden chambers were also increased. bcl-2-expressing cells showed a reduced response to apoptotic stimuli (low-serum conditions or anti-neoplastic drugs). Large branched colonies were formed in Matrigel from ARObcl-2 cells but not from parental cells. Finally, ARObcl-2 cells showed a decreased latency of tumor appearance when injected into immunodeficient mice. Potentiation of the malignant phenotype of ARO cells by bcl-2 was not ascribed to altered expression of (i) cytokine/growth factors (IL-4, IL-6, IL-8, IL-10, IL-12, TGF-alpha, TGF-beta), (ii) thyroid-specific transcripts (TG, TPO, TSH-R, PIGF, PAX-8) or (iii) genes influencing tumor aggressiveness [VEGF, HMGI (Y), HMGI-C]. Our data indicate that bcl-2 potentiates the malignant phenotype of ARO cells not only by limiting the response to apoptotic stimuli but also by enhancing proliferation and tumor aggressiveness.